Physician profile
Christina E Riggall
NPI 1134534860
$771.93
in general payments reported to CMS, 2019-2025
19 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.97 · 2022: $93.48 · 2023: $127 · 2024: $268 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $169.14 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $102.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Alkermes, INC. | $81.07 | 2023-2024 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $80.88 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $66.88 | 2022-2024 | Rexulti, Abilify Asimtufii |
| Amarin Pharma, INC. | $39.70 | 2021 | |
| Abbvie INC. | $27.54 | 2023-2024 | |
| Averitas Pharma INC. | $22.61 | 2025 | Qutenza |
| E.R. Squibb & Sons, L.L.C. | $22.07 | 2024 | Cobenfy |
| Abbott Laboratories | $20.78 | 2022 | |
| Axsome Therapeutics, INC. | $18.87 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $17.31 | 2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.01 | 2025 | Caplyta |
| Pfizer INC. | $15.84 | 2021 | |
| Ibsa Pharma INC. | $14.97 | 2024 | Tirosint, Licart |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $14.40 | 2024 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.18 | 2024 | Xifaxan |
| Exact Sciences Corporation | $13.95 | 2024 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Riggall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.